|
1
|
Parkin DM: International variation.
Oncogene. 23:6329–6340. 2004. View Article : Google Scholar
|
|
2
|
Garfinkel L, Boring CC and Heath CW:
Changing trends. An overview of breast cancer incidence and
mortality. Cancer. 74:222–227. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Polyak K, Porter DA, Krop IE, Nasser S,
Sgroi D, Kaelin CM, Marks JR and Riggins G: On the birth of breast
cancer. Biochim Biophys Acta. 1552:1–13. 2001.PubMed/NCBI
|
|
4
|
Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S,
Rostom A, Stuart RK, al-Mulhim FA, al-Amri A, al-Muhanna FA and
Ajarim D: Locally advanced breast cancer in Saudi Arabia: high
frequency of stage III in a young population. Breast cancer in the
eastern province of Saudi Arabia. Med Oncol. 16:95–103. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neuhausen SL: Ethnic differences in cancer
risk resulting from genetic variation. Cancer. 86:2575–2582. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perera NM and Gui GP: Multi-ethnic
differences in breast cancer: current concepts and future
directions. Int J Cancer. 106:463–467. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Polyak K: Molecular alterations in ductal
carcinoma in situ of the breast. Curr Opin Oncol. 14:92–96. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
9
|
Bargonetti J and Manfredi JJ: Multiple
roles of the tumor suppressor p53. Curr Opin Oncol. 14:86–91. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soussi T, Legros Y, Lubin R, Ory K and
Schlichtholz B: Multifactorial analysis of p53 alteration in human
cancer: a review. Int J Cancer. 57:1–9. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olivier M, Langerod A, Carrieri P, Bergh
J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche
I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A,
Niederacher D, Kato S, Ishioka C, Hainaut P and Borresen-Dale AL:
The clinical value of somatic TP53 gene mutations in 1,794 patients
with breast cancer. Clin Cancer Res. 12:1157–1167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hartmann A, Blaszyk H, McGovern RM,
Schroeder JJ, Cunningham J, De Vries EM, Kovach JS and Sommer SS:
p53 gene mutations inside and outside of exons 5–8: the patterns
differ in breast and other cancers. Oncogene. 10:681–688.
1995.PubMed/NCBI
|
|
13
|
Berns EM, Foekens JA, Vossen R, Look MP,
Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL,
Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ,
Portengen H, Bakker B and Klijn JG: Complete sequencing of TP53
predicts poor response to systemic therapy of advanced breast
cancer. Cancer Res. 60:2155–2162. 2000.PubMed/NCBI
|
|
14
|
Olivier M and Hainaut P: TP53 mutation
patterns in breast cancers: searching for clues of environmental
carcinogenesis. Semin Cancer Biol. 11:353–360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lowe SW, Ruley HE, Jacks T and Housman DE:
p53-dependent apoptosis modulates the cytotoxicity of anticancer
agents. Cell. 74:957–967. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Borresen-Dale AL: TP53 and breast cancer.
Hum Mutat. 21:292–300. 2003. View Article : Google Scholar
|
|
17
|
Geisler S, Borresen-Dale AL, Johnsen H,
Aas T, Geisler J, Akslen LA, Anker G and Lonning PE: TP53 gene
mutations predict the response to neoadjuvant treatment with
5-fluorouracil and mitomycin in locally advanced breast cancer.
Clin Cancer Res. 9:5582–5588. 2003.PubMed/NCBI
|
|
18
|
Langerod A, Zhao H, Borgan O, Nesland JM,
Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL and Jeffrey SS:
TP53 mutation status and gene expression profiles are powerful
prognostic markers of breast cancer. Breast Cancer Res. 9:R302007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartmann A, Blaszyk H, Kovach JS and
Sommer SS: The molecular epidemiology of p53 gene mutations in
human breast cancer. Trends Genet. 13:27–33. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pharoah PD, Day NE and Caldas C: Somatic
mutations in the p53 gene and prognosis in breast cancer: a
meta-analysis. Br J Cancer. 80:1968–1973. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olivier M, Eeles R, Hollstein M, Khan MA,
Harris CC and Hainaut P: The IARC TP53 database: new online
mutation analysis and recommendations to users. Hum Mutat.
19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eachkoti R, Hussain I, Afroze D, Aejazaziz
S, Jan M, Shah ZA, Das BC and Siddiqi MA: BRCA1 and TP53 mutation
spectrum of breast carcinoma in an ethnic population of Kashmir, an
emerging high-risk area. Cancer Lett. 248:308–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hill KA and Sommer SS: p53 as a mutagen
test in breast cancer. Environ Mol Mutagen. 39:216–227. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hedau S, Jain N, Husain SA, Mandal AK, Ray
G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS and Das BC: Novel
germline mutations in breast cancer susceptibility genes BRCA1,
BRCA2 and p53 gene in breast cancer patients from India. Breast
Cancer Res Treat. 88:177–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Faille A, De Cremoux P, Extra JM, Linares
G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M
and Calvo F: p53 mutations and overexpression in locally advanced
breast cancers. Br J Cancer. 69:1145–1150. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsuda H, Iwaya K, Fukutomi T and Hirohashi
S: p53 mutations and c-erbB-2 amplification in intraductal and
invasive breast carcinomas of high histologic grade. Jpn J Cancer
Res. 84:394–401. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saitoh S, Cunningham J, De Vries EM, et
al: p53 gene mutations in breast cancers in midwestern US women:
null as well as missense-type mutations are associated with poor
prognosis. Oncogene. 9:2869–2875. 1994.PubMed/NCBI
|
|
28
|
Nagai MA, Schaer Barbosa H, Zago MA,
Araujo Silva W Jr, Nishimoto IN, Salaorni S, Guerreiro Costa LN,
Silva Araujo M, Caldas Oliveira AG, Mourao Neto M and Brentani MM:
TP53 mutations in primary breast carcinomas from white and
African-Brazilian patients. Int J Oncol. 23:189–196. 2003.
|
|
29
|
Kouidou S, Agidou T, Kyrkou A, Andreou A,
Katopodi T, Georgiou E, Krikelis D, Dimitriadou A, Spanos P,
Tsilikas C, Destouni H and Tzimagiorgis G: Non-CpG cytosine
methylation of p53 exon 5 in non-small cell lung carcinoma. Lung
Cancer. 50:299–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reh BD, DeBord DG, Butler MA, Reid TM,
Mueller C and Fajen JM: O(6)-methylguanine DNA adducts associated
with occupational nitrosamine exposure. Carcinogenesis. 21:29–33.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goldman R and Shields PG: Food mutagens. J
Nutr. 133(Suppl 3): 965S–973S. 2003.PubMed/NCBI
|
|
32
|
Schroeder JC, Conway K, Li Y, Mistry K,
Bell DA and Taylor JA: p53 mutations in bladder cancer: evidence
for exogenous versus endogenous risk factors. Cancer Res.
63:7530–7538. 2003.PubMed/NCBI
|
|
33
|
Hecht SS and Hoffmann D: N-nitroso
compounds and man: sources of exposure, endogenous formation and
occurrence in body fluids. Eur J Cancer Prev. 7:165–166. 1998.
|
|
34
|
Zaidi SN, Laidlaw I, Howell A, Potten CS,
Cooper DP and O’Connor PJ: Normal human breast xenografts activate
N-nitrosodimethylamine: identification of potential target cells
for an environmental nitrosamine. Br J Cancer. 66:79–83. 1992.
View Article : Google Scholar
|
|
35
|
Scharer OD: Chemistry and biology of DNA
repair. Angew Chem Int Ed Engl. 42:2946–2974. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao EH, Fan XJ, Yuan XH, Xin SM, Liu YY
and Yu HT: Levels of O6-methylguanine acceptor protein
in extracts of human breast tumor tissues. Cancer Biochem Biophys.
12:53–58. 1991.
|
|
37
|
Lozano JC, Nakazawa H, Cros MP, Cabral R
and Yamasaki H: G-->A mutations in p53 and Ha-ras genes in
esophageal papillomas induced by N-nitrosomethylbenzylamine in two
strains of rats. Mol Carcinog. 9:33–39. 1994.
|
|
38
|
Mir MM, Dar NA, Gochhait S, Zargar SA,
Ahangar AG and Bamezai RN: p53 mutation profile of squamous cell
carcinomas of the esophagus in Kashmir (India): a high-incidence
area. Int J Cancer. 116:62–68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siddiqi M, Kumar R, Fazili Z,
Spiegelhalder B and Preussmann R: Increased exposure to dietary
amines and nitrate in a population at high risk of oesophageal and
gastric cancer in Kashmir (India). Carcinogenesis. 13:1331–1335.
1992. View Article : Google Scholar : PubMed/NCBI
|
